Heron Therapeutics, Inc.
HRTX
$2.48
$0.093.77%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 40.78M | 32.81M | 36.02M | 34.67M | 34.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.78M | 32.81M | 36.02M | 34.67M | 34.23M |
| Cost of Revenue | 13.41M | 13.92M | 14.95M | 13.05M | 13.69M |
| Gross Profit | 27.38M | 18.89M | 21.07M | 21.62M | 20.55M |
| SG&A Expenses | 23.20M | 23.35M | 27.52M | 26.42M | 13.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.61M | 37.27M | 42.47M | 39.47M | 26.85M |
| Operating Income | 4.17M | -4.46M | -6.45M | -4.80M | 7.38M |
| Income Before Tax | 3.66M | -4.85M | -9.24M | -3.16M | -10.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.66M | -4.85M | -9.24M | -3.16M | -10.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.66M | -4.85M | -9.24M | -3.16M | -10.72M |
| EBIT | 4.17M | -4.46M | -6.45M | -4.80M | 7.38M |
| EBITDA | 4.75M | -3.88M | -5.80M | -4.11M | 8.10M |
| EPS Basic | 0.02 | -0.03 | -0.06 | -0.02 | -0.07 |
| Normalized Basic EPS | 0.02 | -0.02 | -0.04 | -0.01 | 0.03 |
| EPS Diluted | 0.02 | -0.03 | -0.06 | -0.02 | -0.07 |
| Normalized Diluted EPS | 0.02 | -0.02 | -0.04 | -0.01 | 0.03 |
| Average Basic Shares Outstanding | 153.15M | 152.83M | 152.31M | 151.20M | 153.20M |
| Average Diluted Shares Outstanding | 153.15M | 152.83M | 152.31M | 151.20M | 153.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
